DOSIS-WIRKUNGSBEZIEHUNGEN BEI CARCINOGENEN SUBSTANZEN

[1] BLUM HF, 1959, CUL

[2] Bryan WR, 1943, J NATL CANCER I, V3, P503

[3] PHARMAKOLOGISCHE KRITERIEN FUR DIE PRUFUNG VON KREBS-CHEMOTHERAPEUTIKA [J]. NATURWISSENSCHAFTEN, 1956, 43 (21) : 486 - 492

[4] DRUCKREY H, 1960, ARCH EXP PATHOL PH, V238, P67

[5] DRUCKREY H, 1948, Z NATURFORSCH, V3B, P254

[6] DRUCKREY H, 1960, ARCH EXP PATH PHARM, V238, P232

[7] HORTON AW, 1955, CANCER RES, V15, P701

[8] PRIGGE R, 1935, ARCH EXP PATH PHARM, V191, P281

[9] SCHMAHL D, 1956, Z KREBSFORSCH, V61, P230

[1] BLUM HF, 1959, CUL

[2] Bryan WR, 1943, J NATL CANCER I, V3, P503

[3] PHARMAKOLOGISCHE KRITERIEN FUR DIE PRUFUNG VON KREBS-CHEMOTHERAPEUTIKA [J]. NATURWISSENSCHAFTEN, 1956, 43 (21) : 486 - 492

[4] DRUCKREY H, 1960, ARCH EXP PATHOL PH, V238, P67

[5] DRUCKREY H, 1948, Z NATURFORSCH, V3B, P254

[6] DRUCKREY H, 1960, ARCH EXP PATH PHARM, V238, P232

[7] HORTON AW, 1955, CANCER RES, V15, P701

[8] PRIGGE R, 1935, ARCH EXP PATH PHARM, V191, P281

[9] SCHMAHL D, 1956, Z KREBSFORSCH, V61, P230